These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage. Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783 [TBL] [Abstract][Full Text] [Related]
6. Clinical value of blocking IL-6 receptor. Mima T; Nishimoto N Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268 [TBL] [Abstract][Full Text] [Related]
7. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Oldfield V; Dhillon S; Plosker GL Drugs; 2009; 69(5):609-32. PubMed ID: 19368420 [TBL] [Abstract][Full Text] [Related]
8. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis. Mitchell E; Jones G Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984 [TBL] [Abstract][Full Text] [Related]
9. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317 [TBL] [Abstract][Full Text] [Related]
10. [Tocilizumab in rheumatoid arthritis]. Rueda Gotor J; Blanco Alonso R Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769 [TBL] [Abstract][Full Text] [Related]
11. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Yokota S; Kishimoto T Expert Rev Clin Immunol; 2010 Sep; 6(5):735-43. PubMed ID: 20828281 [TBL] [Abstract][Full Text] [Related]
12. Tocilizumab: the first interleukin-6-receptor inhibitor. Sebba A Am J Health Syst Pharm; 2008 Aug; 65(15):1413-8. PubMed ID: 18653811 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Tanaka E; Inoue E; Hoshi D; Shimizu Y; Kobayashi A; Sugimoto N; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H Mod Rheumatol; 2015 Jul; 25(4):503-13. PubMed ID: 25547018 [TBL] [Abstract][Full Text] [Related]
15. A review of sarilumab for the treatment of rheumatoid arthritis. Lee EB Immunotherapy; 2018 Jan; 10(1):57-65. PubMed ID: 29043871 [TBL] [Abstract][Full Text] [Related]
16. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)]. Nasonov EL Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275 [TBL] [Abstract][Full Text] [Related]
17. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Zhang X; Peck R Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882 [TBL] [Abstract][Full Text] [Related]
19. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Jones G Expert Rev Clin Immunol; 2010 Mar; 6(2):189-95. PubMed ID: 20402381 [TBL] [Abstract][Full Text] [Related]
20. The clinical efficacy of tocilizumab in rheumatoid arthritis. Mircic M; Kavanaugh A Drugs Today (Barc); 2009 Mar; 45(3):189-97. PubMed ID: 19436841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]